Retatrutide Dosing: The Doses and Titration Schedules Actually Tested in Its Clinical Trials

Tens of thousands of people search "retatrutide dosing" every month, and most of what ranks for it is happy to hand back a number — a starting dose, a weekly increase, a target maintenance amount. What almost none of it says plainly is that there is no FDA-approved retatrutide dose to report, because there is no FDA-approved retatrutide product at all. Our explainer on retatrutide's regulatory status covers why in detail: retatrutide remains an investigational molecule moving through Eli Lilly's TRIUMPH Phase 3 program, with a Biologics License Application not even planned for filing until the first quarter of 2027. Until FDA reviews and approves a specific product, at a specific dose, with a specific label, there is no dosing standard for this site — or any legitimate source — to hand a reader.

What we can report, precisely and with every figure traced back to the trial that produced it, is what dose and titration schedules retatrutide's own clinical trials have actually used. That's a real, answerable question, and it's a different question from "what should I take." Every number below describes a trial protocol, administered under direct clinical supervision, with investigators adjusting or halting a specific participant's dose based on how that participant responded. None of it is a template for self-administration.

Phase 2, obesity: titration was itself part of the experiment

The trial that first characterized retatrutide's dose-response relationship — 338 adults, 48 weeks, published in the New England Journal of Medicine — didn't just test different maintenance doses. It deliberately varied the starting dose independently of the target dose, to see whether a gentler on-ramp changed tolerability. Participants were randomized to one of six retatrutide regimens or placebo: 1 mg with no titration; a 4 mg maintenance dose reached from either a 2 mg or a 4 mg starting dose; an 8 mg maintenance dose reached from either a 2 mg or a 4 mg starting dose; or a 12 mg maintenance dose reached from a 2 mg starting dose — each injected once weekly for 48 weeks¹. The trial's own results section states the reason for testing two starting doses at 4 mg and 8 mg directly: the most common adverse events were gastrointestinal, they were dose-related, and they were "partially mitigated with a lower starting dose¹." That's a titration schedule being tested as a variable, not a fixed recommendation — the trial didn't yet know which starting dose was better when it began.

Phase 2, type 2 diabetes: an even finer-grained titration comparison

A second, contemporaneous Phase 2 trial in 281 adults with type 2 diabetes — published in The Lancet — went a step further, directly comparing escalation speed, not just the starting number. Its arms: 0.5 mg with no titration; a 4 mg maintenance dose reached with escalation from a 2 mg start, compared against a 4 mg dose given with no escalation at all; an 8 mg maintenance dose reached via "slow escalation" (2 mg start) compared against the same 8 mg dose reached via "fast escalation" (4 mg start); and a 12 mg maintenance dose reached via escalation from a 2 mg start — each once weekly, compared against placebo and against 1.5 mg dulaglutide as an active comparator, for 36 weeks². Gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) occurred in 35% of participants across the combined retatrutide arms — ranging from 13% in the lowest-dose (0.5 mg) group up to 50% in the 8 mg fast-escalation group specifically, against 13% on placebo². That's a real, trial-reported signal that how fast a dose is escalated — not just what the final maintenance dose is — affects GI tolerability, which is exactly the kind of variable a clinical trial protocol exists to test in a controlled way and an individual reader cannot safely replicate alone.

Phase 3: the TRIUMPH program's dosing structure, and what changed

The doses carried into Lilly's Phase 3 program are not identical to the Phase 2 lineup. The peer-reviewed design paper for the TRIUMPH clinical trials — four Phase 3, randomized, double-blind studies enrolling over 5,800 participants across obesity, obstructive sleep apnea, and knee osteoarthritis — states that TRIUMPH-1 and TRIUMPH-2 test retatrutide maintenance doses of 4 mg, 9 mg, and 12 mg against placebo, while TRIUMPH-3 (run in a population with established cardiovascular disease) and TRIUMPH-4 test only the higher 9 mg and 12 mg doses³. Notice the shift: Phase 2's 1 mg / 4 mg / 8 mg / 12 mg dose ladder became Phase 3's 4 mg / 9 mg / 12 mg ladder — a change Lilly's own paper attributes to "safety and efficacy data as well as exposure-response modelling from phase 1 and 2 retatrutide studies³." In plain terms, the sponsor itself revised which specific milligram amounts were worth testing further, based on what the earlier trials showed — which is a useful thing to know if you're evaluating whether any single number, from any source, should be treated as fixed.

The design paper also specifies how titration works structurally in TRIUMPH-1 and TRIUMPH-2: "a fixed dose escalation regimen" spanning the first 16 weeks of the trial, followed by a 64-week maintenance period — 80 weeks in total. Critically, it isn't a one-way ratchet: "a permanent dose reduction is permitted for management of gastrointestinal adverse events or inadequate oral intake that has not improved with other mitigations," and dose reduction is also allowed for participants who reach a BMI of 22 kg/m² or lower, or who report perceived excessive weight loss³. That's a protocol built around ongoing clinical judgment adjusting an individual's dose in both directions — not a schedule a reader could follow unsupervised even if they wanted to.

ClinicalTrials.gov's own record for TRIUMPH-1 (NCT05929066) independently confirms the shape of this design: three active retatrutide dose arms plus placebo, randomized, double-blind, an 80-week placebo-controlled treatment period, and a separate 24-week extension period for participants who continue on retatrutide afterward⁶.

What TRIUMPH-1's own topline numbers say about titration in practice

TRIUMPH-1 has not yet been published as a full peer-reviewed manuscript — Lilly has so far reported it via topline press release, and that distinction matters enough to repeat rather than skip. With that caveat stated plainly, Lilly's own May 2026 release does include a detail directly relevant to titration: the 4 mg maintenance dose was "reached with only a single escalation step," while participants assigned to the higher 9 mg and 12 mg doses required a more gradual, multi-step climb to reach their target⁴. The same release reports that discontinuation due to adverse events rose with dose — 4.1% at 4 mg, 6.9% at 9 mg, and 11.3% at 12 mg, against 4.9% on placebo⁴ — a pattern consistent with the Phase 2 finding that faster or higher escalation carries a real tolerability cost, even though the specific numbers here come from a press release rather than a published trial report.

For participants with a BMI of 35 or higher who completed the full 80-week placebo-controlled period and continued into the trial's extension, the protocol included what Lilly's release describes as "a blinded escalation to maximum tolerated dose (9 mg or 12 mg)" for an additional 24 weeks — reaching an average of 30.3% weight loss by week 104 in that subgroup⁴. That's a trial-protocol-managed, further titration step layered on top of the initial 80-week schedule, decided by investigators based on each participant's tolerance, not a number a reader outside that trial has access to replicate.

The one completed, peer-reviewed Phase 3 trial: TRANSCEND-T2D-1

Separate from the TRIUMPH obesity program, a different Phase 3 trial — TRANSCEND-T2D-1, in adults with type 2 diabetes inadequately controlled by diet and exercise alone — has actually been completed and published in full, in The Lancet, as of June 2026. It randomized 537 participants 1:1:1:1 to retatrutide 4 mg, 9 mg, 12 mg, or placebo, once weekly, over 40 weeks, with the primary endpoint being change in HbA1c⁵. This is the strongest evidence in this article specifically because it's a completed, peer-reviewed publication rather than a topline announcement — the same evidentiary bar the rest of this site holds every other trial citation to. Its own reported dose-response pattern echoes what the earlier trials found: larger reductions in both HbA1c and body weight at higher doses, with treatment-emergent adverse events again concentrated in mild-to-moderate gastrointestinal events that "subsided over time⁵." Study-drug discontinuation due to adverse events ran 2–5% across the three retatrutide doses, against 0% on placebo⁵.

The bottom line

Across five separate trials — two Phase 2 studies, a peer-reviewed completed Phase 3 trial, and two Phase 3 trials so far reported only via topline press release — a consistent pattern holds: retatrutide's trials titrate up gradually from a low starting dose toward one of several tested maintenance doses, under direct investigator supervision, with the explicit ability to slow down, pause, or permanently reduce a participant's dose based on how they respond. That pattern is worth understanding if you're trying to make sense of what "retatrutide dosing" even means as a concept. It is not, and cannot be, a schedule for you to follow on your own — there is still no FDA-approved retatrutide product, no approved label, and therefore no dose this site, or any other legitimate source, can responsibly recommend. The only way to receive retatrutide today under real clinical and regulatory oversight is enrollment in one of Lilly's own trials.

If you already have an actual prescribed number in hand from a legitimate clinical context, our retatrutide reconstitution calculator will do the vial-to-syringe arithmetic on it — pure math on whatever you enter, not a check on the product or a substitute for the trial-level supervision described above. And for the fuller regulatory picture — why there's no approved product, no legal purchase pathway, and no compounding exception for retatrutide the way there is for FDA-approved tirzepatide — see our companion article on retatrutide's approval status.